Proposed Phase II Study on Antisense Therapy Targeting Apolipoprotein(a) (right click on the image below to download to your desktop)
POSITIVE CLINICAL DATA FROM Lp(a) LOWERING DRUG ISIS-APO(a)Rx PUBLISHED IN THE LANCET
The paper titled "Antisense therapy targeting apolipoprotein(a): a randomized, double-blind, placebo-controlled phase 1 study" (Tsimikas et al, The Lancet 2015 : published online today), reported data from the Phase 1 study evaluating single and multiple ascending doses of ISIS-APO(a)Rx in healthy volunteers with elevated Lp(a) concentrations of 25 nmol/L (100 mg/L) or more. Results of this study demonstrated potent, dose-dependent, selective reductions of plasma Lp(a) up to 89% (mean reduction up to 78%) in patients treated with ISIS-APO(a)Rx.
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.
Tsimikas S1, Viney NJ2, Hughes SG2, Singleton W2, Graham MJ2, Baker BF2, Burkey JL2, Yang Q2, Marcovina SM3, Geary RS2, Crooke RM2, Witztum JL4.
ISIS-APO(a)Rx results in potent, dose-dependent, selective reductions of plasma Lp(a). The safety and tolerability support continued clinical development of ISIS-APO(a)Rx as a potential therapeutic drug to reduce the risk of cardiovascular disease and calcific aortic valve stenosis in patients with elevated Lp(a) concentration.